KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Free Cash Flow (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Free Cash Flow for 13 consecutive years, with -$81.8 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 48.27% to -$81.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$279.9 million through Dec 2025, down 51.75% year-over-year, with the annual reading at -$279.9 million for FY2025, 51.75% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$81.8 million at Xenon Pharmaceuticals, down from -$72.0 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$14.0 million in Q2 2021, with the low at -$81.8 million in Q4 2025.
  • Average Free Cash Flow over 5 years is -$39.8 million, with a median of -$36.0 million recorded in 2023.
  • The sharpest move saw Free Cash Flow rose 11.71% in 2022, then tumbled 103.04% in 2023.
  • Over 5 years, Free Cash Flow stood at -$21.2 million in 2021, then crashed by 74.72% to -$37.1 million in 2022, then increased by 4.32% to -$35.5 million in 2023, then plummeted by 55.49% to -$55.2 million in 2024, then crashed by 48.27% to -$81.8 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$81.8 million, -$72.0 million, and -$64.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.